Stocks TelegraphStocks Telegraph
Stock Ideas

ATRC Company Profile and Key Details

NASDAQ : ATRC

AtriCure

$36.92
-0.19-0.51%
At Close 4:00 PM
69.13
B-ESG ScoreESG Rating

Price Chart

Stock Price Today

AtriCure, Inc. (ATRC) stock declined over -0.51%, trading at $36.92 on NASDAQ, down from the previous close of $37.11. The stock opened at $37.16, fluctuating between $36.22 and $37.20 in the recent session.

Stock Snapshot

37.11
Prev. Close
1.84B
Market Cap
36.22
Day Low
-60.52
P/E Ratio
-0.61
EPS (TTM)
-0.81
Cash Flow per Share
37.16
Open
49.72M
Number of Shares
37.195
Day High
96.44%
Free Float in %
10.04
Book Value
299.85K
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Feb 09, 202637.1637.5736.2236.92312.43K
Feb 06, 202636.7137.6836.2237.11398.35K
Feb 05, 202636.6837.9636.1136.20438.51K
Feb 04, 202638.0738.3236.5236.80531.52K
Feb 03, 202637.0038.1236.8338.07770.85K
Feb 02, 202637.1037.5336.7436.82433.55K
Jan 30, 202636.9537.6736.2636.93361.63K
Jan 29, 202637.6137.9936.4736.95488.32K
Jan 28, 202638.3338.3937.3437.77346.79K
Jan 27, 202638.1339.2837.3538.41471.83K
Jan 26, 202639.0639.9638.5038.51442.21K
Jan 23, 202640.0240.9139.0339.07375.59K
Jan 22, 202639.3040.5339.0740.02391.48K
Jan 21, 202638.4639.7538.4639.27556.89K
Jan 20, 202638.0839.1937.2638.42525.14K
Jan 16, 202641.1941.8038.9339.06728.31K
Jan 15, 202637.3141.7937.3141.461.03M
Jan 14, 202636.4737.8936.0637.37631.17K
Jan 13, 202637.5437.9536.3336.40620.45K
Jan 12, 202641.5541.9636.7637.64903.11K

Contact Details

Mason, OH 45040

United States

https://www.atricure.com513 755 4100

About Company

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Company Information

Employees1300
Beta1.41
Sales or Revenue$399.25M
5Y Sales Change%0.457%
Fiscal Year EndsDecember
SectorHealthcare
IndustryMedical - Instruments & Supplies

Company Overview

AtriCure, Inc. (NASDAQ:ATRC) closed at $36.92 USD, losing -$0.19 (-0.51%) from the previous close of $37.11. The stock is currently mid-range between its 52-week high and low $28.29 and $43.18. With a market capitalization of about $1.84 billion, AtriCure, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.41). Key stats such as the average daily volume over the past year has been around 508.49 thousand shares, volume is running light vs its 52-week average. Headquartered in Mason, OH, AtriCure, Inc. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Michael H. Carrel, the company employs approximately 1,300 people and listed since August 05, 2005. AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -2.74%, SMA50 -5.58%, SMA200 4.65%). The stock’s 14-day RSI is 44.21 (neutral), while the ATR of 1.61 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -14.5% below its high and over 30.51% above its low. Average 10-day trading volume of 463.83 thousand shares is in line with the 3-month average of 499.46 thousand, indicating normal recent market interest.

Dividend & Fair Value

AtriCure, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$23.49. This means the shares are trading below this model’s fair value.

Shareholding & Insider Activity

AtriCure, Inc. has 49.72 million shares outstanding. The public float is 47.97 million shares, elevated short interest at 4.93% of float. This equals 2.37 million shares. The short ratio is 4.91 days. Institutional investors hold 102.96% of the float. Insiders own 3.19%. CARREL MICHAEL H holds 504.80 thousand shares, Wade M. Andrew has 145.12 thousand shares and Privitera Salvatore has 103.29 thousand shares. Over the past six months, insider transactions show net selling. They sold 31.17 thousand shares across 7 transactions.

Financial & Profitability Overview

Over the trailing twelve months, AtriCure generated $399.25M in revenue, or $8.62 per share. Gross margin was 74.49%, operating margin -7.79%, and net profit margin -7.62%. Returns are negative, with ROA at -4.96% and ROE at -6.53%.
On valuation metrics, AtriCure trades at a P/E of -61.41, P/S of 3.55 and P/B of 3.71. The current ratio is 3.87 and quick ratio is 2.85. Operationally, the company’s inventory turnover is 1.65 and cash conversion cycle is 194.22 days. Debt-to-equity is 0.16, supported by a cash flow-to-debt ratio of 0.56.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, AtriCure posted revenue of $399.25M, down slightly from $330.38M in the prior quarter. Gross profit was $297.42M (margin 74.49%). Operating income was - $31.10M (margin -7.8%). Net income was- $30.44M (EPS - $0.66).
The company ended the quarter with $137.29M in cash and short-term investments, a total debt of $74.49M, and net debt of - $9.82M. Total assets were $613.93M, with equity of $466.17M. Financials further reflected stability, with operating cash flow of $4.42M, free cash flow of - $37.57M, and capital expenditures of - $42.00M.

Frequently Asked Questions

What is the current AtriCure, Inc. (ATRC) stock price?
AtriCure, Inc. (NASDAQ: ATRC) stock price is $36.92 in the last trading session. During the trading session, ATRC stock reached the peak price of $37.20 while $36.22 was the lowest point it dropped to. The percentage change in ATRC stock occurred in the recent session was -0.51% while the dollar amount for the price change in ATRC stock was - $0.19.
ATRC's industry and sector of operation?
The NASDAQ listed ATRC is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector. AtriCure, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ATRC?
Ms. Tonya A. Austin SPHR
Senior Vice President of HR
Mr. Karl S. Dahlquist C.C.E.P., CCEP, J.D.
Chief Legal Officer
Ms. Angela L. Wirick CPA
Chief Financial Officer
Mr. Justin J. Noznesky
Chief Marketing & Strategy Officer
Mr. Salvatore Privitera J.D.
Chief Technical Officer
Mr. Douglas J. Seith
Chief Operating Officer
Valerie Storch-Willhaus
Vice President of Corporation Marketing & Communications
Mr. Amalio Telenti M.D., Ph.D.
Executive Vice President & Chief Data Officer
Mr. Michael H. Carrel
Chief Executive Officer, Pres & Director
Dr. Vinayak Doraiswamy Ph.D.
Chief Scientific Officer
Ms. Deborah Yount
Chief HR Officer
How ATRC did perform over past 52-week?
ATRC's closing price is 30.5% higher than its 52-week low of $28.29 where as its distance from 52-week high of $43.18 is -14.5%.
How many employees does ATRC have?
Number of ATRC employees currently stands at 1,300.
Link for ATRC official website?
Official Website of ATRC is: https://www.atricure.com
How do I contact ATRC?
ATRC could be contacted at phone 513 755 4100 and can also be accessed through its website. ATRC operates from 7555 Innovation Way, Mason, OH 45040, United States.
How many shares of ATRC are traded daily?
ATRC stock volume for the day was 299.85K shares. The average number of ATRC shares traded daily for last 3 months was 508.49K.
What is the market cap of ATRC currently?
The market value of ATRC currently stands at $1.84B with its latest stock price at $36.92 and 49.72M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph